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Decay-accelerating factor ([DAF] CD55) is a glycosylphosphatidylinositol-anchored membrane 
inhibitor of complement with broad clinical relevance. Here, we establish an additional and 
unexpected role for DAF in the suppression of adaptive immune responses in vivo. In both 
C57BL/6 and BALB/c mice, deficiency of the Daf1 gene, which encodes the murine homologue 
of human DAF, significantly enhanced T cell responses to active immunization. This phenotype 
was characterized by hypersecretion of interferon (IFN)-
 
  
 
and interleukin (IL)-2, as well as 
down-regulation of the inhibitory cytokine IL-10 during antigen restimulation of lymphocytes 
in vitro. Compared with wild-type mice, Daf1
 
 
 
/
 
  
 
mice also displayed markedly exacerbated 
disease progression and pathology in a T cell–dependent experimental autoimmune 
encephalomyelitis (EAE) model. However, disabling the complement system in Daf1
 
 
 
/
 
  
 
mice 
normalized T cell secretion of IFN-
 
  
 
and IL-2 and attenuated disease severity in the EAE 
model. These findings establish a critical link between complement and T cell immunity and 
have implications for the role of DAF and complement in organ transplantation, tumor 
evasion, and vaccine development.
 
Decay-accelerating factor ([DAF] CD55) is a
glycosylphosphatidylinositol (GPI)-anchored
membrane inhibitor of complement (1, 2). It
inhibits complement activation by interfering
with the function of C3 and C5 convertases in
both the classical and alternative pathways (1,
2). Clinically, DAF has been found to be defi-
cient on affected blood cells and platelets of
paroxysmal nocturnal hemoglobinuria patients,
contributing to the heightened sensitivity of such
cells to autologous complement attack (3–5). In
many types of human carcinomas, on the other
hand, up-regulation of DAF is observed, sug-
gesting that circumvention of complement-
mediated tumoricidal activity may constitute a
tumor evasion mechanism (6–8). DAF is also a
therapeutic target in the setting of xenotrans-
plantation. Transgenic expression of human
DAF on porcine endothelial cells is used as a
strategy to thwart complement-mediated hy-
peracute rejection in pig to primate xenotrans-
plantation (9–11).
A number of previous studies have sug-
gested that DAF may participate in T cell
function as a GPI molecule in lipid rafts (12–
14). Additionally, DAF has been identified as
a ligand for an activation-associated, seven-
transmembrane lymphocyte receptor, CD97
(15–18); however, the significance of DAF–
CD97 interaction remains unknown. We pre-
viously generated, by gene targeting, a mouse
that is deficient in the Daf1 gene that encodes
the murine homologue of human DAF (19).
As expected, we found that Daf1
 
 
 
/
 
  
 
mice are
more susceptible to complement-mediated in-
flammatory injury (19–21). Unexpectedly, when
bred onto the autoimmune disease–prone
MRL/lpr background, Daf1
 
 
 
/
 
  
 
mice devel-
oped exacerbated lymphadenopathy and sple-
nomegaly (22), raising the possibility that DAF
may also function as a negative regulator of
adaptive immunity in vivo. In this study, we
investigated this possibility by studying the T
cell responses of WT and Daf1
 
 
 
/
 
  
 
mice to ac-
tive immunization. We show that deficiency
of Daf1 significantly enhanced T cell response
to active immunization via a complement-
dependent mechanism. Thus, our findings
identify DAF as a key molecule that regulates
the interplay between complement and T cell
immunity in vivo. This conclusion has implica-
tions for the immunobiology and therapeutics
of DAF in organ transplantation, tumor evasion,
and vaccine development.
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Abbreviations used: DAF, 
decay-accelerating factor; EAE, 
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gelatin veronal-buffered saline; 
MOG, myelin oligodendrocyte 
glycoprotein; SEB, Staphylo-
coccus enterotoxin B; T reg cell, 
T regulatory cell. 
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RESULTS
Daf1
 
    
 
mouse lymphocytes responded more vigorously 
to antigen restimulation
 
To evaluate T lymphocyte immunity in Daf1
 
 
 
/
 
  
 
mice, we
immunized C57BL/6-Df1
 
 
 
/
 
  
 
and C57BL/6 WT mice with
OVA in the presence of CFA. 12 d later, LNs were isolated
and cells were prepared and restimulated with OVA in cul-
ture. Fig. 1, A and B, shows that compared with cells from
WT mice, LN cells from Daf1
 
 
 
/
 
  
 
mice proliferated more
vigorously and secreted more IFN-
 
 
 
. Restimulation of LN
cells from Daf1
 
 
 
/
 
  
 
mice immunized with a different antigen,
myelin oligodendrocyte glycoprotein (MOG) peptide (MOG
38–50) bearing a T cell epitope (23), produced similar results,
with Daf1
 
 
 
/
 
  
 
cells displaying increased proliferation and
IFN-
 
  
 
secretion compared with WT cells (Fig. 1, C and D).
With both antigens, similar results were obtained when sple-
nocytes alone were prepared from the immunized mice and
restimulated (not depicted). Therefore, we combined LN
cells and splenocytes in subsequent experiments unless speci-
fied otherwise.
Figure 1. Responses of C57BL/6 WT and Daf1    mouse lympho-
cytes to antigen restimulation. (A–D) LN cells from four mice in each 
group were pooled and restimulated with antigen in vitro (in triplicate 
assays) 12 d after immunization with OVA (A and B) or MOG 38–50 (C and 
D). Cell proliferation (A and C) and IFN-  production (B and D) were deter-
mined. Similar results were obtained with splenocytes (not depicted). 
Results are representative of three independent experiments. (E–H) Spleen 
and LN cells from each mouse were combined and restimulated with antigen 
in vitro (in triplicate assays) 60 d after immunization with OVA, and the 
production levels of four cytokines were determined (each bar represents 
a single mouse, and four mice were used in each group). The x axis repre-
sents antigen concentration during restimulation assays. Asterisks desig-
nate levels that were below the detection limits. Results are representative 
of three independent experiments. 
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To determine if the increased restimulation response per-
sists in memory T cells of Daf1
 
 
 
/
 
  
 
mice, we immunized
C57BL/6-Df1
 
 
 
/
 
  
 
and C57BL/6 WT mice with OVA and
tested the recall responses of their lymphocytes 60 d later.
Fig. 1 E shows that cultured lymphocytes from Daf1
 
 
 
/
 
  
 
mice
again secreted significantly increased amounts of IFN-
 
 
 
, as
noted in the previous experiment, and they also produced
higher levels of IL-2 and IL-4 (Fig. 1, F and G). On the
other hand, we found that the production of the inhibitory
cytokine IL-10 by the Daf1
 
 
 
/
 
  
 
cells was markedly reduced
(Fig. 1 H).
Next, we investigated whether the effect of Daf1 defi-
ciency on the restimulation response of mouse T cells is spe-
cific to C57BL/6 mice. Using a procedure similar to the
one outlined above, we immunized BALB/c-Daf1
 
 
 
/
 
  
 
and
BALB/c WT mice with OVA and determined the restimu-
lation responses of their lymphocytes after 12 d. Fig. 2 shows
that as was the case with the C57BL/6-Df1
 
 
 
/
 
  
 
mice, restim-
ulated lymphocytes from BALB/c-Daf1
 
 
 
/
 
  
 
mice displayed
increased IFN-
 
  
 
and decreased IL-10 production as com-
pared with those of WT control animals (Fig. 2, A and B).
However, in contrast to C57BL/6-Df1
 
 
 
/
 
  
 
mice, the pro-
duction of IL-4 by restimulated BALB/c-Daf1
 
 
 
/
 
  
 
mouse T
cells was significantly reduced. Thus, there appears to be a
strain difference between C57BL/6 and BALB/c mice in
that Daf1 deficiency in BALB/c mice caused a more polar-
ized Th1 cell response to immunization.
 
Enhanced restimulation response by Daf1
 
 
 
/
 
  
 
lymphocytes 
tracks with T cells
 
To determine if the hyperresponse phenotype of Daf1
 
 
 
/
 
 
 
mouse lymphocytes was caused by altered APC function or
was associated with T cells, we purified CD4
 
  
 
T cells
and APCs from OVA-immunized C57BL/6-Df1
 
 
 
/
 
  
 
and
Figure 2. Responses of BALB/c WT and Daf1    mouse lymphocytes 
to antigen restimulation. Spleen and LN cells from each mouse were 
combined and restimulated with OVA in vitro (in triplicate assays) 12 d 
after immunization, and cytokine production was determined (each bar 
represents a single mouse, and four mice were used in each group). The x 
axis represents OVA concentration used for restimulation. Asterisks desig-
nate levels that were below the detection limits. Results are representative 
of two independent experiments.
Figure 3. Enhanced restimulation response of Daf1    spleen and LN 
cell tracks with T cells. (A) CD4  T cells and APCs were purified from 
spleen and LN cells of immunized C57BL/6 WT and Daf1 /  mice (pooled 
from four animals in each group and immunized with OVA for 12 d) and 
cross-matched in antigen-restimulation assays in vitro (2   105 CD4  cells/
well or 106 APCs/well alone or in combination with or without 25  g/ml 
OVA, triplicate assays for each treatment). IFN-  levels in the cell culture 
medium were assayed after 48 h of culture. B shows ELISPOT assays of IFN- –
secreting T cells in lymphocyte cultures of C57BL/6 WT and Daf1 /  mice. 
Spleen and LN cells from immunized C57BL/6 WT and Daf1 /  mice (pooled 
from four animals in each group and immunized with OVA for 12 d) were 
restimulated with 25  g/ml OVA for 40 h (six replicate assays, 105cells/well). 
Results are representative of two independent experiments. 
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C57BL/6 WT mice and cross-matched them in the restimu-
lation assay. Fig. 3 A shows that the genotype of APCs had
no impact on IFN-
 
  
 
production by either WT or Daf1
 
 
 
/
 
 
 
CD4
 
  
 
T cells, whereas Daf1
 
 
 
/
 
  
 
CD4
 
  
 
T cells secreted more
IFN-
 
  
 
than WT CD4
 
  
 
T cells regardless of whether they
were mixed with WT or Daf1
 
 
 
/
 
  
 
APCs. Using ELISPOT,
we also found that there were significantly more IFN-
 
 
 
–
secreting T cells in the lymphocyte cultures of Daf1
 
 
 
/
 
  
 
mice
than in those of WT mice (Fig. 3 B). These results suggested
that clonal expansion and/or survival of antigen-primed
CD4
 
  
 
cells was enhanced in Daf1
 
 
 
/
 
  
 
mice in vivo.
 
Hyper T cell response in Daf1
 
    
 
mice was largely 
dependent on complement
 
Next, we investigated if the hyper response of Daf1
 
 
 
/
 
 
 
mouse T cells to immunization was caused by the lack of
DAF available to function as a complement inhibitor. If this
were the case, removal of the complement system from
Daf1
 
 
 
/
 
  
 
mice should attenuate or reverse the phenotype. To
test this hypothesis, we produced C57BL/6-Df1
 
 
 
/
 
 
 
-C3
 
 
 
/
 
 
 
mice by crossing Daf1
 
 
 
/
 
  
 
mice with C3
 
 
 
/
 
  
 
mice. We then
compared the memory T cell response to antigen restimula-
tion in WT, C3
 
 
 
/
 
 
 
, Daf1
 
 
 
/
 
 
 
, and Daf1
 
 
 
/
 
 
 
-C3
 
 
 
/
 
  
 
mice us-
ing IFN-
 
  
 
and IL-2 secretion as readouts. As expected, lym-
phocytes from Daf1
 
 
 
/
 
  
 
mice secreted much higher levels of
IFN-
 
  
 
and IL-2 than those of WT mice (Fig. 4, A and B).
Significantly, we found that deletion of the C3 gene from
Daf1
 
 
 
/
 
  
 
mice normalized IFN-
 
  
 
and IL-2 secretion such
that the levels of these cytokines produced by Daf1
 
 
 
/
 
 
 
-C3
 
 
 
/
 
 
lymphocytes were similar to those of WT cells (Fig. 4, A
and B). The same result was noted in ELISPOT assays of
IFN- –secreting T cells in lymphocyte cultures of these
mice (Fig. 4, C and D). In contrast to the clear reversing ef-
fect on IFN-  and IL-2 production, however, C3 deficiency
did not consistently correct the IL-10 defect of Daf1 /  mice
(not depicted). These results suggested that hypersecretion of
Figure 4. Hyper T cell response in Daf1    mice is largely dependent 
on complement. In the experiment shown in A–D, C57BL/6 WT, C3 / , 
Daf1 / , and Daf1 / -C3 /  mice were immunized with OVA. After 105 d, 
spleen and LN cells (pooled from four animals in each group) were restim-
ulated in vitro (triplicate wells) and assayed for IFN-  (A) and IL-2 (B) pro-
duction. The frequency of IFN- –secreting T cells in the lymphocyte cultures 
was also determined by ELISPOT (C; six replicate assays, 105 cells/well, 
stimulated with 25  g/ml OVA for 40 h). The average number of IFN- –
secreting T cells per well is shown in D. Results are representative of two 
independent experiments. Experiments using splenocytes or LN cells alone 
gave similar results to those shown in A and B (not depicted). In the exper-
iments shown in E and F, C57BL/6-Df1 /  mice were treated with an anti-
C5 mAb or an isotype-matched IgG control antibody. As another control, 
C57BL/6 WT mice were also treated with the isotype-matched IgG. 12 d 
after immunization, spleen and LN cells (pooled from four mice in each 
group) were restimulated with 25  g/ml OVA in culture for 40 h. IFN-  
production was assessed by ELISA (E; triplicate wells) or ELISPOT (F; six 
replicate wells at 105 cells/well).JEM VOL. 201, February 21, 2005 571
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IFN-  by Daf1 /  mouse T cells was largely dependent on a
functional complement system but was probably not second-
ary to the defect in IL-10 production. Because DAF regu-
lates C3 activation by inhibiting both the classical pathway
C3 convertase C4b2a and the alternative pathway C3 con-
vertase C3bBb, it remains to be determined by which path-
way C3 was activated in the Daf1 /  mice and whether C4
also plays a critical role in producing the observed cellular
immunity phenotype in Daf1 /  mice.
It is of interest that compared with WT cells, there was a
reduction in IFN-  and IL-2 production by C3 /  mouse T
cells (Fig. 4, A–D). This suggested that complement may
play an adjuvant role in WT mice as well in facilitating T
cell responses to active immunization. It is also notable that
Daf1 / -C3 /  mouse T cells produced more IFN-  and
IL-2 than C3 /  mouse T cells (Fig. 4, A–D). This implied
that Daf1 deficiency rendered T cells more responsive even
in the absence of C3, suggesting the existence of a separate,
C3-independent mechanism of T cell regulation by DAF. It
is clear, however, that the putative C3-independent mecha-
nism only played a marginal role in the Daf1 /  mouse phe-
notype under study.
To better understand the complement-dependent mech-
anism of T cell regulation by Daf1, we depleted C5 in
C57BL/6-Df1 /  mice by administering an anti-C5 mAb
(24). We then investigated the effect of C5 depletion on
IFN-  production by Daf1 /  mouse T cells in response to
antigen restimulation in the OVA immunization model. We
found that as with C3 gene inactivation in Daf1 / -C3 / 
mice, C5 depletion in Daf1 /  mice also rescued their hyper
T cell response phenotype (Fig. 4, E and F). This result im-
plicated the anaphylatoxin C5a and/or the lytic pathway ef-
fector C5b-9 as the principal mediator(s) responsible for the
observed Daf1 /  mouse phenotype.
Daf1    but not Daf1   -C3    mice developed exacerbated 
experimental autoimmune encephalomyelitis (EAE)
To further confirm the inhibitory effect of DAF on T cell
immunity, we studied the sensitivity of Daf1 /  mice to
EAE induced by a MOG peptide (MOG 38–50), which
bears a T cell epitope. Although complement is involved in
some experimental models of EAE, as recently demonstrated
for EAE induction by recombinant MOG in CD59a knock-
out mice (25), a previous study showed that EAE disease in
mice induced by a closely related MOG peptide, MOG 35–
55, was mainly T cell driven and independent of comple-
ment (26). We found that Daf1 /  mice immunized with
MOG 38–50 developed a markedly exacerbated disease phe-
notype compared with similarly treated WT mice (Fig. 5).
This was indicated by an increased average daily clinical
score after disease onset (Fig. 5 A) and a higher endpoint
mortality rate (80 vs. 10%; Table I) in the Daf1 /  group.
Histologically, Daf1 /  mouse spinal cord sections had more
abundant inflammatory infiltrates (Fig. 5, B–E) and a higher
Figure 5. Daf1    but not Daf1   -C3    mice developed exacer-
bated EAE. MOG 38–50 was used to induce EAE in groups of C57BL/6 WT, 
C3 / , Daf1 / , and Daf1 / -C3 /  mice. Compared with WT mice, Daf1 /  
but not Daf1 / -C3 /  mice developed markedly exacerbated EAE disease 
(A). There was no significant difference between WT and C3 /  mice in 
daily clinical scores. One animal each in the WT and C3 /  group died, at 
days 36 and 14, respectively. 8 of the 10 animals in the Daf1 /  group 
died, 1 each at days 16, 25, 31, 36, 37, and 39, and 2 at day 35. B–E show 
representative histological pictures of spinal cords of WT (B), Daf1 /  (C), 
C3 /  (D), and Daf1 / -C3 /  (E) mice harvested from a separate experi-
ment at 15 d after disease induction, demonstrating that there were sig-
nificantly more inflammatory cell infiltrates in the Daf1 /  mouse spinal 
cords (a magnification of 400). F–H show that compared with that of WT 
(F) and Daf1 / -C3 /  (H) mice, the spinal cords of Daf1 /  (G) mice 
stained less intensely with luxol fast blue, suggesting increased demye-
lination (a magnification of 100).REGULATION OF COMPLEMENT AND T CELL IMMUNITY | Liu et al. 572
degree of demyelination (Fig. 5, F–H). Deficiency of C3
from WT mice did not significantly attenuate EAE disease
severity, whereas deficiency of C3 in Daf1 /  mice rescued
the enhanced EAE disease phenotype (Fig. 5 and Table I).
Thus, in this prototypical T cell–mediated autoimmune dis-
ease model, Daf1 /   but not Daf1 / -C3 /   mice had
markedly exacerbated disease progression and pathology.
These results are in agreement with in vitro assays of Daf1 / 
mouse T cell function and highlight the relevance of our
findings in a pathophysiological setting.
Daf1    mouse T cells responded similarly to superantigen 
stimulation and had no defect in T regulatory cells 
(T reg cells)
Several mechanisms, not mutually exclusive of one another,
may underlie the observed hyper T cell response phenotype
of Daf1 /  mice. These include enhanced sensitivity of T
cells to activation stimuli, enhanced clonal expansion, and/
or diminished contraction of the antigen-specific T cell pool
and decreased T reg cell number and/or activity. To deter-
mine if Daf1 /  mouse T cells are intrinsically more respon-
sive to activation stimuli, we stimulated splenocytes from
C57BL/6 WT and Daf1 /  mice with the bacterial superan-
tigen Staphylococcus enterotoxin B (SEB) and examined
their proliferative responses, CD69 expression, and IFN- 
production. We detected no significant differences between
the WT and Daf1 /  mice in these assays (Fig. 6, A–D). In
separate experiments, we also observed no significant differ-
ence in either the number or function of the naturally oc-
curring T reg cells in naive C57BL/6 and Daf1 /  mice (Fig.
6, E–G).
DISCUSSION
Here we demonstrated, both by in vitro assays and by a T
cell–mediated autoimmune disease model, that deficiency of
DAF in mice caused a hyper T cell response to active immu-
nization. Daf1 /  T cells proliferated more vigorously and
secreted more IFN-  in response to antigen restimulation,
and Daf1 /  mice developed markedly exacerbated EAE dis-
ease when immunized with a T cell epitope-bearing MOG
peptide. Although our data revealed a potential C3-indepen-
dent effect of Daf1 on T cell function that warrants further
investigation, this C3-independent mechanism contributed
marginally to the Daf1 /  mouse phenotype under study.
Instead, the inhibitory effect of Daf1 on T cell immunity in
this model appeared to be largely indirect and mediated by
complement, as IFN-  assays determined that inactivation of
the C3 gene or depletion of C5 protein from Daf1 /  mice
rescued the hyper T cell response phenotype. C3 deficiency
also reversed EAE disease exacerbation in Daf1 /  mice. Al-
though the role of complement as a natural adjuvant in B
cell priming and memory maintenance is well recognized
(27–29), recently, evidence has emerged that suggests that
complement may also play an instrumental role in optimiz-
ing T cell response to viral or allogeneic antigens (30–33).
Our finding that DAF, a GPI-anchored membrane protein
known for its complement-inhibiting activity, negatively
regulates T cell immunity is in accord with this emerging
concept and suggests that complement regulatory proteins
may significantly affect the interplay between complement
and T cell immunity in vivo.
The fact that increased IFN-  and decreased IL-10
production was observed in both C57BL/6-Daf1 /  and
BALB/c-Daf1 /  mice strongly suggests that the observed
abnormality in T cell immune response was caused by Daf1
deficiency and not by genetic background differences be-
tween WT and Daf1 /  mice. Notwithstanding this obser-
vation, we found that Daf1 deficiency had an opposing in-
fluence on IL-4 production by activated T cells in C57BL/6
and BALB/c mice. Consequently, Daf1 deficiency in
BALB/c mice produced a hyper T cell response that was also
markedly biased toward a Th1 cell phenotype. This diver-
gent effect of Daf1 deficiency on IL-4 production likely re-
flected intrinsic differences in T cell immunity between the
two mouse strains. The BALB/c strain of mice is well
known for its tendency to mount a stronger Th2 cell im-
mune response, and strain-dependent manifestations of phe-
notypes have been documented in other immune regulatory
gene knockout studies (34, 35). For example, deletion of the
programmed cell death-1 immunoinhibitory coreceptor gene
caused autoimmune dilated cardiomyopathy in BALB/c but
not C57BL/6 mice (35).
Our data indicate that augmented T cell response to anti-
gen immunization in Daf1 /  mice is not caused by en-
hanced susceptibility of the T cells to activation stimuli, as
WT and mutant mouse splenocytes responded similarly to
activation by the bacterial superantigen SEB (Fig. 6, A–D).
DAF is widely expressed on peripheral tissues as well as on T
and B lymphocytes, macrophages, and dendritic cells (1, 2,
36, 37). It is therefore important to elucidate the mecha-
nism(s) by which DAF suppresses T cell immunity in vivo.
Although we found that Daf1 /  APCs functioned normally
during antigen restimulation assays in vitro (Fig. 3 A), the re-
sponses of Daf1 /  T cells and APCs in vivo during the
Table I. Daf1    mice developed exacerbated EAE
Genotype Incidence Mortality Days of onseta Maximum disease scorea
Daf1    10/10 (100%) 1/10 (10%) 11.3   0.67 3.0   1.1
Daf1    10/10 (100%) 8/10 (80%) 10.6   0.70 4.6   0.8
C3    9/9 (100%) 1/9 (11%) 10.9    0.78 3.1   0.9
Daf1   -C3    8/8 (100%) 0/8  (0%) 15.0    1.51 2.2   0.59
aMean   SD.JEM VOL. 201, February 21, 2005 573
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priming phase of immunization are yet to be assessed. Such a
question might be addressed by T cell adoptive transfer ex-
periments using TCR transgenic mice carrying either a nor-
mal or mutated Daf1 gene. It is possible that DAF deficiency
in peripheral tissues (e.g., skin) enhances complement activa-
tion and promotes local inflammation at the immunization
sites, creating a more favorable environment for APC matu-
ration and/or antigen capture and presentation. An alterna-
tive but not mutually exclusive hypothesis is that in the set-
ting of active immunization, a lack of DAF leads to enhanced
systemic inflammation and generation of a cytokine milieu
that favors the survival of antigen-primed T cells. Both hy-
Figure 6. Daf1    mouse T cells responded similarly to SEB stimu-
lation and had no defect in T reg cells. In the experiments shown in 
A–D, splenocytes from C57BL/6 WT and Daf1 /  mice (n   4 mice in each 
group) were stimulated with SEB at the indicated concentrations and their 
proliferative response (A), CD69 expression on CD4  (B) and CD8  (C) T 
cells, and IFN-  production (D) were compared. No significant difference 
was detected between the two groups in any of the measurements. Results 
are representative of two independent experiments. E and F show that 
there was no significant difference between WT and Daf1 /  mice in the 
number of naturally occurring T reg cells. Percentage of CD25  cells 
among spleen CD4  T cells was determined by FACS analysis in seven WT 
and eight Daf1 /  mice (E). Foxp3 expression in purified spleen CD4  T 
cells (n   3 samples in each group, with each sample representing spleno-
cytes pooled from two mice before CD4  cell selection) was determined by 
real-time RT-PCR (F). Foxp3 levels are shown as relative expression (R.E.)
to the housekeeping gene L32. G shows that there was no difference 
between CD4  CD25  T cells from WT (W) or Daf1 /  (K) mice in their 
ability to inhibit anti-CD3–stimulated proliferation of CD4  CD25  T cells. 
W , CD4  CD25  T cells from WT; K , CD4  CD25  T cells from Daf1 / ; 
W , CD4  CD25  T cells from WT; K , CD4  CD25  T cells from Daf1 / ; 
APC, irradiated WT splenocytes.REGULATION OF COMPLEMENT AND T CELL IMMUNITY | Liu et al. 574
potheses are consistent with the demonstrated requirement of
C5, a critical complement protein that when activated, gives
rise to the anaphylatoxin C5a and the lytic pathway effector
C5b-9 in the development of the hyper T cell response phe-
notype of the mutant mice (Fig. 4, E and F).
Another potential mechanism for increased T cell re-
sponse to antigen immunization in Daf1 /  mice is decreased
T reg cell number or function (38). T reg cells suppress im-
mune responses to self- and nonself antigens (38). Two major
T reg cell populations have been described so far: naturally
occurring T reg cells and IL-10–secreting T reg cells (38).
Both types of T reg cells express CD25 on their surface, but
only the naturally occurring T reg cells express the transcrip-
tional repressor Foxp3 as a specific marker gene (38, 39). A
link between T reg cells and a membrane complement regu-
latory protein was demonstrated in a recent study whereby
coengagement of CD3 and the complement regulator CD46,
in the presence of IL-2, induced an IL-10–secreting T reg
cell phenotype in human CD4  T cells (40). We found no
defect in naive Daf1 /  mice with regard to the number or
function of their naturally occurring T reg cells (Fig. 6, E–G).
Although the reduced production of IL-10 by Daf1 /  lym-
phocytes would be compatible with the hypothesis of im-
paired differentiation or function of IL-10–secreting T reg
cells, it remains to be established whether the defect in IL-10
production originated from T reg cells or other IL-10–secret-
ing cells such as macrophages. An argument against the im-
paired IL-10–secreting T reg cell hypothesis is the observa-
tion that C3 deficiency rescued the hyper T cell response
phenotype of Daf1 /  mice but did not consistently correct
their IL-10 defect, suggesting that reduced IL-10 production
was not central to the Daf1 /  mouse phenotype.
The notion that DAF suppresses T cell immunity
through complement regulation either locally (on T cells,
APCs, or in tissue microenvironments) or systemically has
several clinical implications. For example, transgenic expres-
sion of human DAF on porcine endothelial cells is used as a
strategy to circumvent complement-mediated hyperacute
rejection in xenotransplantation (9–11). Our findings here
suggest that such a strategy may have the added benefit of
suppressing T cell–mediated acute or chronic rejection. In a
separate clinical setting, expression of DAF is up-regulated
on many types of human tumors and this has been inter-
preted as conferring an advantage to the tumor cells in their
resistance to complement lysis (6–8). We suggest that a more
significant ramification of DAF overexpression on tumor
cells might be that it provides protection from T cell–medi-
ated tumorecidal activity. In this context, it is of interest to
note that two tumor-associated antigens, 791Tgp72 and SC-1
antigen, which had been used successfully as targets for tu-
mor imaging and T cell or antibody immunotherapy in
Phase I and II clinical trials, respectively, were recently iden-
tified as DAF (41, 42). Finally, the markedly enhanced
memory T cell response phenotype in Daf1 /  mice raises
the prospect that DAF might be exploited as a therapeutic
target for effective vaccine development.
MATERIALS AND METHODS
Mice. We studied 6–8-wk-old male C57BL/6-Df1 /   and BALB/c-
Daf1 /  mice. Two DAF genes, Daf1 and Daf2, are present in the mouse
(43, 44). Daf1 encodes a GPI-anchored DAF protein and is widely ex-
pressed on mouse tissues (43–45). Daf2 is predominantly expressed in the
mouse testis and its major transcript encodes a transmembrane form of DAF
(43–45). The Daf1 /  mouse was generated by gene targeting as described
previously (19). The mouse was subsequently backcrossed for nine genera-
tions with C57BL/6 or BALB/c mice to derive either the C57BL/6-Df1 / 
or BALB/c-Daf1 /  mice used in this investigation. No alteration in the
expression of Daf2 or two other membrane complement regulators, CD59a
and Crry, was observed on blood cells or several tissues examined in these
Daf1 /  mice (19, 20, 22, 46; unpublished data). Gender- and age-matched
WT C57BL/6 and BALB/c mice were obtained from The Jackson Labora-
tory. Six time-backcrossed C57BL/6-C3 /  mice were obtained from The
Jackson Laboratory. These mice were backcrossed for one more generation
in our colony to derive the seven time-backcrossed C57BL/6-C3 /  mice
used in this study. C57BL/6-Df1 / -C3 /  mice were generated by crossing
nine time-backcrossed C57BL/6-Df1 /  mice with seven time-backcrossed
C57BL/6-C3 /  mice. Mice were housed in a specific pathogen-free facil-
ity and all experimental protocols were approved by the Institutional Ani-
mal Care and Use Committee of the University of Pennsylvania.
Reagents. Chicken OVA was from Difco Laboratories. Mouse MOG 38–
50 peptide was synthesized and purified on HPLC by Research Genetics.
Pertussis toxin was from List Biological Laboratories. SEB was from Toxin
Technology Inc. CFA, [3H]thymidine, gelatin veronal-buffered saline
(GVBS)2 , and PE-goat anti–rabbit IgG were from Sigma-Aldrich. A mono-
clonal rat anti–mouse CD59a (47) was provided by P. Morgan (University of
Wales, Cardiff, UK). Two hamster anti–mouse DAF mAbs, Riko-3 and
Riko-4 (48), were provided by N. Okada (Nagoya City University, Nagoya,
Japan). A polyclonal rabbit anti–mouse Crry was provided by M. Holers
(University of Colorado Health Sciences Center, Denver, CO). FITC-don-
key anti–rat IgG ([Fab ]2) was from Jackson ImmunoResearch Laboratories.
PE-goat anti–hamster IgG, purified hamster anti–mouse CD3e (clone 145-
2C11), APCcy7-rat anti–mouse CD4, PE-rat anti–mouse CD8, FITC-ham-
ster anti–mouse CD69, and FITC-rat anti–mouse CD25 were from BD
Biosciences. Microbead-conjugated antibodies against CD4, CD8, CD19,
CD90, and DX5 were from Miltenyi Biotec. Quantitative ELISA kits for
mouse IFN- , IL-2, IL-4, and IL-10 were from BD Biosciences. The anti–
mouse C5 hybridoma (BB5.1) was originally generated by immunization of
a C5-deficient mouse as described previously (49). Mouse ascites for the
anti-C5 mAb were produced by Cocalico Biologicals Inc. The anti-C5 mAb
was partially purified from mouse ascites using the caprylic acid method, in-
volving ammonium sulfate precipitation followed by dialysis (50). An isotype
control mAb (MOPC21, IgG1, lyophilized protein) was from Sigma-Aldrich.
It was resuspended in PBS before use.
Mouse immunization. Mice were immunized by subcutaneous injection
in the flank with 100  g OVA or 300  g MOG 38–50 peptide emulsified
in an equal volume of CFA. 12 d later, inguinal and axillary LNs and/or
spleens were collected for single cell preparation used in antigen restimula-
tion assays in vitro. For memory T cell response, antigen restimulation as-
says were performed 60–110 d after immunization.
Anti-C5 mAb treatment. C57BL/6-Df1 /  mice were treated with the
anti-C5 mAb or the isotype-matched IgG control antibody (1 mg/mouse,
i.p.) every 4 d starting from 1 d before OVA immunization. As a separate
control group, C57BL/6 WT mice were treated with the isotype-matched
IgG control antibody. C5 depletion in the anti-C5 mAb-treated mice was
confirmed by testing the relative hemolytic activities of their sera collected
at day 4 after anti-C5 mAb treatment using antibody-sensitized RBCs from
Daf1 / /Crry / /C3 /  triple knockout mice (51). In brief, RBCs from
Daf1 / /Crry / /C3 /  mice (2–3    107 cells in a 100- l volume of
GVBS2 ) were sensitized with 10 mg/ml 34-3C, a murine anti-erythrocyteJEM VOL. 201, February 21, 2005 575
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monoclonal autoantibody (46). After washing twice with PBS and once
with GVBS2 , the sensitized RBCs were exposed to the assay sera at 1:10
or 1:5 in GVBS2  for 30 min at 37 C. The percent RBC lysis was estimated
by measuring the OD value of the supernatant at 414 nm as described pre-
viously (46). Using this assay, we found that  10% of the hemolytic activity
remained at day 4 in mice receiving a single anti-C5 injection. In contrast,
the hemolytic activity of mice receiving the control IgG antibody remained
similar to that of untreated mice.
Antigen restimulation of lymphocytes in vitro. For cytokine assays,
LN cells or a mixture of LN cells and splenocytes from immunized mice
were cultured at 1.5   106 cells/well in 0.2 ml DMEM (Life Technologies)
containing 10% FBS, 2 mM L-glutamine, 10 mM Hepes, 0.1 mM nones-
sential amino acids, 100 U penicillin-streptomycin, 50  M 2-mercaptoeth-
anol, and 1 mM sodium pyruvate. Cells were stimulated with 0, 5, and 25
 g/ml OVA or MOG 38–50. Cell culture supernatants were collected at
40 (for IFN-  assay) or 96 h (for IL-2, IL-4, and IL-10 assay). For T cell
proliferation assays, LN cells were seeded at 0.5   106 cells/well. After 48 h,
[3H]thymidine (1  Ci/well) was added to the culture medium, and the cells
were harvested 16 h later. Cellular incorporation of radioactivity was deter-
mined using a flatbed   counter (Wallac).
SEB stimulation of lymphocytes in vitro. To assess the general sensi-
tivity of Daf1 /  mouse T cells to activation stimuli, splenocytes were pre-
pared from naive C57BL/6 WT and Daf1 /  mice and were stimulated
with the bacterial superantigen SEB. Cells were plated at 1.0   106 cells/
well in 96-well, round-bottom culture plates and stimulated with SEB (1
pg/ml to 100 ng/ml) in a final volume of 0.2 ml medium. Expression of the
early activation marker CD69 on CD4  and CD8  T cells was examined at
18 h by FACS after three-color staining with APCcy7–anti-CD4, PE–anti-
CD8, and FITC–anti-CD69. In parallel experiments, cell culture superna-
tants were collected at 40 h to determine IFN-  production. For prolifera-
tion assays, splenocytes were plated at 0.5   106 cells/well and stimulated
with SEB as described above for 48 h and then pulsed with [3H]thymidine
(1  Ci/well). They were cultured for another 16 h before being harvested.
Purification of CD4  T cells and APCs. CD4  T cells were isolated
by two rounds of selection. First, a CD4  T cell–enriched cell population
was isolated from combined LN cells and splenocytes of immunized mice
by negative selection using a magnetic bead–based CD4  T cell isolation kit
(Miltenyi Biotec). These cells were then stained with FITC-conjugated
anti-CD4 and positive cells were subsequently selected by FACS. The pu-
rity of CD4  T cells prepared in this manner was consistently  99%. APCs
were purified from the same source of spleen and LN cells by negative se-
lection using mAbs against mouse CD4, CD8, CD19, CD90, as well as
anti-NK cells (DX5) and an autoMACS cell sorter (Miltenyi Biotec).
Analysis of T reg cell number and function. Splenocytes from naive
C57BL/6 WT and Daf1 /  mice were stained for CD4 and CD25, and the
percentage of CD25  cells in the CD4  T cell population was determined
after FACS analysis. The number of naturally occurring T reg cells was esti-
mated by real-time RT-PCR analysis of Foxp3, a marker gene specifically
expressed in T reg cells. For this experiment, CD4  T cells were purified by
negative selection from splenocytes (three samples in each genotype, with
each sample representing splenocytes pooled from two mice) as described
above. Total RNAs were extracted from 106 CD4  cells using 1 ml TRIzol
reagent (Invitrogen Life Technologies), and first strand cDNA was synthe-
sized by reverse transcription using random hexamer primers. Foxp3
mRNA was quantified using the ABI 7900 Real-Time PCR System (Ap-
plied Biosystems). Amplification was performed in a total volume of 15  l
for 40 cycles, and products were detected using SYBR Green I dye (Ap-
plied Biosystems). Samples were run in duplicate and relative expression
level was determined by normalization to the housekeeping gene L32 (52)
with results presented as relative expression units. Primer sequences used
were as follows: L32, forward: 5 -GGAAACCCAGAGGCATTGAC-3 ,
reverse: 5 -TCAGGATCTGGCCCTTGAAC-3 ; Foxp3, forward: 5 -
GGCCCTTCTCCAGGACAGA-3 , reverse: 5 -GCTGATCATGGCT-
GGGTTGT-3 .
To assess T reg cell function, the abilities of CD4  CD25  T cells from
WT and Daf1 /  mice to inhibit anti-CD3–stimulated proliferation of
CD4  CD25  T cells were compared. CD4  T cells were first purified from
splenocytes (pooled from six mice in each genotype) by negative selection
as described above. After staining with FITC–anti-CD25, CD4  CD25 
and CD4  CD25  T cells were separated by FACS sorting. For functional
assays, CD4  CD25  T cells (5   104 cells /well) from WT or Daf1 / 
mice were mixed with equal numbers of CD4  CD25  T cells and irradi-
ated splenocytes (both from C57BL/6 WT mice). Triplicate assays were
performed for each treatment group. The cells were stimulated for 72 h
with 500 ng/ml anti-CD3, and [3H]thymidine (1  Ci /well) was added 16 h
before cell harvest. Cellular incorporation of radioactivity was determined
using a flatbed   counter (Wallac).
ELISPOT assay. IFN-   ELISPOT assay was performed using an
ELISPOT kit from BD Biosciences. In brief, 96-well plates were coated
overnight at 4 C with a capture antibody (5.0  g/ml anti–mouse IFN- ).
After blocking for 2 h, the plates were washed three times with PBS. LN
cells and splenocytes were seeded at 105 cells/well and cultured for 40 h. Af-
ter removing the cells, the plates were washed extensively with PBS/0.05%
Tween-20, and 2.0  g/ml of a detection antibody, biotinylated anti–mouse
IFN- , was then added. After incubating at room temperature for 2 h, the
plates were washed again and incubated with Streptavidin–horseradish per-
oxidase for 1 h before being developed by addition of the horseradish per-
oxidase substrate. The plates were then analyzed using the ImmunoSpot
Analyzer and associated software to determine the number, size, and colori-
metric density of positive spots.
Induction of EAE. Mice were immunized by subcutaneous injection in
the flank with 300  g MOG 38–50 in 0.1 ml PBS emulsified in an equal
volume of CFA containing 5 mg/ml Mycobacterium tuberculosis H37RA
(Difco Laboratories). Pertussis toxin (100 ng/mouse) was administered in-
travenously on the day of immunization and 2 d later. Mice were examined
daily for signs of EAE and scored as follows: 0, no disease; 1, tail paralysis; 2,
hind limb weakness; 3, hind limb paralysis; 4, hind limb plus forelimb paral-
ysis; and 5, moribund or dead.
Histological studies. Mice were perfused with PBS and 10% formalin
phosphate. Spinal cords were embedded in paraffin, cut into five pieces, and
then sectioned at 5  m and stained with hematoxylin and eosin or with
luxol fast blue, a myelin-specific stain. The degree of inflammation and de-
myelination in spinal cords was assessed by estimating the percentage of tissue
section areas that were infiltrated by inflammatory cells or negative for my-
elin staining. From each animal, a total of 10 tissue sections from the cervical,
thoracic, lumbar, and sacral spinal cord were examined in a blind fashion.
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